View Older Stories View More Recent Stories

Mar 8, 2022 08:00AM Seelos Therapeutics Receives an Acknowledgement Letter of a Clinical Trial Notification from the Australian Government Department of Health Therapeutic Goods Administration for a Pilot Study of SLS-00
Mar 7, 2022 08:00AM Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update
Feb 28, 2022 08:00AM Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
Dec 21, 2021 04:05PM Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dec 16, 2021 08:00AM Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event
Dec 6, 2021 08:01AM Seelos Therapeutics (SEEL) Issued Composition of Matter Patent in Japan for SLS-007
Dec 6, 2021 08:01AM Seelos Therapeutics Announces Issuance of Composition of Matter Patent in Japan for SLS-007
Nov 24, 2021 08:16AM Seelos Therapeutics (SEEL) Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
Nov 24, 2021 08:16AM Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
Nov 24, 2021 07:16AM Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note
Nov 10, 2021 08:00AM Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium
Nov 8, 2021 08:01AM Seelos Therapeutics (SEEL) Announces FDA Acceptance of IND and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar Ataxia
Nov 8, 2021 08:00AM Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar Ataxia
Nov 2, 2021 08:00AM Seelos Therapeutics to Participate in Two Investor Conferences
Oct 25, 2021 02:00PM Seelos Therapeutics Presents a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
Oct 1, 2021 08:00AM Seelos Therapeutics to Present a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
Sep 9, 2021 08:00AM Seelos Therapeutics to Participate in Two Investor Conferences in September
Sep 2, 2021 08:02AM Seelos Therapeutics (SEEL) Appoints Margaret Dalesandro to its Board
Sep 2, 2021 08:00AM Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of Directors
Sep 1, 2021 08:00AM Seelos Therapeutics Announces Senior Management Appointments
Aug 9, 2021 08:00AM Seelos Therapeutics Announces Mid-Year 2021 Business and Clinical Update
Jul 14, 2021 08:00AM Seelos Therapeutics to Participate in Two Investor Conferences in August
Jul 7, 2021 07:03AM Seelos Therapeutics (SEEL) Announces Positive In Vivo Data Demonstrating Down-Regulation of SNCA mRNA and Protein Expression from a Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 for Parkinson's
Jul 7, 2021 07:00AM Seelos Therapeutics Announces Positive In Vivo Data Demonstrating Down-Regulation of SNCA mRNA and Protein Expression from a Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 for Parkinson's Diseas
Jul 6, 2021 08:00AM Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
Jun 28, 2021 07:00AM Seelos Therapeutics Added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes
Jun 1, 2021 08:00AM Seelos Therapeutics Announces its Inclusion in the First U.S. Listed Exchange Traded Fund (ETF) Focused on Psychedelics
May 27, 2021 07:04AM Seelos Therapeutics (SEEL) Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis
May 27, 2021 07:00AM Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)
May 21, 2021 08:00AM Seelos Therapeutics to Participate in The Benchmark Company Healthcare Conference
May 17, 2021 06:07AM Seelos Therapeutics (SEEL) Reports Positive Topline Data from the Open-Label Study of SLS-002
May 17, 2021 06:00AM Seelos Therapeutics Announces Positive Topline Data from the Open-Label Study of SLS-002 (Intranasal Racemic Ketamine), Demonstrating a Significant Treatment Effect and a Well Tolerated Safety Profile
May 10, 2021 08:00AM Seelos Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference
Apr 20, 2021 07:01AM Seelos Therapeutics (SEEL) Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis
Apr 20, 2021 07:00AM Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)
Apr 19, 2021 08:00AM Seelos Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
Apr 15, 2021 09:00AM Seelos Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference
Apr 6, 2021 07:04AM Seelos Therapeutics (SEEL) Announces Strategic Device Partnership with AptarGroup, Inc.
Apr 6, 2021 07:00AM Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.
Mar 5, 2021 09:02AM Seelos Therapeutics (SEEL) Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorde
Mar 5, 2021 09:00AM Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with M
Feb 18, 2021 07:00AM Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)
Feb 17, 2021 08:00AM Seelos Therapeutics to Participate in the 33rd Annual Roth Conference
Feb 1, 2021 08:00AM Seelos Therapeutics to Participate in Canaccord Genuity's New Paradigms and Treatment Approaches in Mental Health Conference February 3-4
Jan 29, 2021 08:03AM Seelos Therapeutics (SEEL) Announces Issuance of a Patent for Trehalose in Australia
Jan 29, 2021 08:00AM Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in Australia
Jan 28, 2021 10:07AM Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares
Jan 27, 2021 08:00AM Seelos Therapeutics Announces its Inclusion in the First Psychedelic Exchange Traded Fund (ETF)
Jan 26, 2021 08:33AM Seelos Therapeutics (SEEL) Announces Pricing of $31.25 Million Public Offering of Common Stock
Jan 26, 2021 08:30AM Seelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common Stock
View More Recent Stories View Older Stories